Advertisement
Advertisement
U.S. Markets open in 40 mins
Advertisement
Advertisement
Advertisement
Advertisement

Prometheus Biosciences, Inc. (RXDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.06-1.66 (-4.40%)
At close: 04:00PM EST
98.80 +62.74 (+173.99%)
Pre-Market: 08:50AM EST
Advertisement

Prometheus Biosciences, Inc.

9410 Carroll Park Drive
San Diego, CA 92121
United States
858 684 1300
https://www.prometheusbiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark C. McKennaPres, CEO & Chairman2.22MN/A1980
Dr. Keith W. Marshall M.B.A., MBA, Ph.D.Chief Financial Officer971.67kN/A1968
Mr. Mark StenhouseChief Operating Officer679.71kN/A1967
Dr. Allison Luo M.D.Chief Medical Officer827.97kN/A1973
Dr. Olivier Laurent Ph.D.Chief Scientific Officer & Head of R&DN/AN/A1972
Ms. Noel KurdiVP of Investor Relations & CommunicationsN/AN/AN/A
Mr. Timothy K. Andrews Esq.Gen. Counsel & Sec.N/AN/A1979
Ms. Nori EbersoleChief People OfficerN/AN/A1965
Dr. Thierry Dervieux DABCC, Ph.d., Pharm.d.Chief Devel. Officer of Diagnostics & Medical Laboratory DirectorN/AN/A1968
Mr. Chris DoughtyChief Bus. OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Corporate Governance

Prometheus Biosciences, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement